about
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetesRegenerative therapies for diabetic microangiopathyPI3kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune PolarizationThe mechanisms of up-regulation of dendritic cell activity by oxidative stressLaser capture microdissection as a new tool to assess graft-infiltrating lymphocytes gene profile in islet transplantation.Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation.Role of podocyte B7-1 in diabetic nephropathyA novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes.Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model.CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigensChronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.TIM4 Regulates the Anti-Islet Th2 Alloimmune ResponseA report of six cases of familial papillary thyroid cancer.IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response.Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses.Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation.The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US.Metabolomic Profiling in Individuals with a Failing Kidney AllograftLong-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7Immunological applications of stem cells in type 1 diabetes.Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection.B7h (ICOS-L) maintains tolerance at the fetomaternal interfaceTargeting CD22 reprograms B-cells and reverses autoimmune diabetes.Pancreatic islet cell transplant for treatment of diabetes.Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells.Divergent role of donor dendritic cells in rejection versus tolerance of allografts.Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site.The clinical impact of islet transplantation.Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes.Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes.ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration.Abatacept in B7-1-positive proteinuric kidney disease.Immunological and regenerative properties of cord blood stem cells.Strategies to reverse endothelial progenitor cell dysfunction in diabetesThe purinergic system in allotransplantation.Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy.Novel immunological strategies for islet transplantation.
P50
Q24644691-6BB50B7D-E414-4D5E-9F5E-A8F38B5A969AQ27027852-97B30603-4B70-4014-BEF7-A893C7B712CEQ28831131-8F2B4D5C-E730-4230-A0A2-64AB04E32643Q30583882-F0853F0A-C2A4-405A-815B-ABBE15236A92Q33507189-2C369CB1-FBAB-484B-B4E4-1F150361EF36Q33548694-85DBEAAB-DAF1-4ADB-8021-54C75B9407B0Q33814864-E732FC3E-7B6E-43D5-9FFD-5A51AEC9F9F9Q34082857-CB029453-4A85-49A2-9907-288454D99296Q34355278-D3CB9CA1-515C-4275-99DD-600EED3C628CQ34551797-EB96D08D-AAB9-4261-B2DA-0EA4E628F949Q34673098-507257A1-9E3E-4FC2-A7A4-8705920C06F9Q34762482-8B40CB2E-D4FF-4C4B-8C51-87501B8BA1D6Q34780873-BF03B0FE-0EBE-49B4-AE90-BEC982645D9FQ34791435-93479161-731C-4EFD-889F-7CFA4402C6C1Q35084213-7C81CEBE-146B-44B7-9079-DD028054EF1AQ35561097-FD39D259-E3F6-4FA9-BC50-7DA2120A66B0Q35612362-BD028DFB-952C-4DF3-B9D7-BD3CD1728128Q35688334-42C7E70C-0AA6-4591-92A2-08D147B4EFF6Q35976619-4E48AF9A-2FD1-4683-A552-A0EDD2078800Q35980427-A264A291-6F24-441C-9396-11723E8F737FQ36239432-66527F17-5040-489F-B3DC-8A897EA6C280Q36601735-33377521-8FCD-43B4-82D5-2808F8CF0DBCQ36666422-C2C89959-B87B-4E29-9CA0-E2F16CEF2C49Q36796093-D30C4108-6F5A-4E8D-876D-9D2ACCC190C4Q36888297-A10092EB-CA3A-4C86-8312-EF8720EAC751Q36943737-8079BA61-AA46-4E88-8A66-9C0A549744F3Q36993730-AE83AEB0-739A-45A2-B5B4-42BF8579B4A1Q37112525-DE98F8FF-6AAF-4F85-AE36-1FEEF17EBB85Q37123243-FC6E21B2-F596-453C-BDC6-8E2C6F7D8EBBQ37143268-0E7FC0A2-4E33-4719-93BF-ADC58DDE2411Q37283965-54691098-9186-4D93-AA89-1639CD35EABFQ37403188-BE091013-F9EB-4787-8925-2801551B03F8Q37492370-3D02A1D5-0393-41D0-98BF-5F90884EAB49Q37570020-6048C8FC-8CD0-4443-96E6-EC1C60234C6CQ37633142-F0AA4733-155F-4DD7-A2B5-91028BA5075AQ37744150-84EECDE9-E6F3-4BF2-BC33-E23208D43686Q37999783-F199608F-B8B4-4E11-8F5F-755A54FE647DQ38179081-6AAF84CD-6C5C-4C2D-9AA2-44DEE82C7DFFQ38217417-9AE94C52-A233-4CF3-A7B5-5F06D4C3A64EQ38228385-CCA3EA28-001D-4797-828C-C43EF19FF816
P50
description
researcher ORCID ID = 0000-0002-1093-7724
@en
wetenschapper
@nl
name
Paolo Fiorina
@ast
Paolo Fiorina
@en
Paolo Fiorina
@es
Paolo Fiorina
@nl
type
label
Paolo Fiorina
@ast
Paolo Fiorina
@en
Paolo Fiorina
@es
Paolo Fiorina
@nl
prefLabel
Paolo Fiorina
@ast
Paolo Fiorina
@en
Paolo Fiorina
@es
Paolo Fiorina
@nl
P1153
7004237874
P21
P31
P496
0000-0002-1093-7724